ketendoКлиническая и экспериментальная тиреоидологияClinical and experimental thyroidology1995-54722310-3787Endocrinology Research Centre10.14341/ket20095337-42ketendo-4492Research ArticleСтатьиArticlesЩитовидная железа и сердцеThyroid and the HeartKarasAalexka14@mail.ruObrezanAobrezan@medem.ru20091509200953ТОМ 5, №3 (2009)3742Copyright © Karas A., Obrezan A., 20092009Karas A., Obrezan A.Karas A., Obrezan A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cet-endojournals.ru/jour/article/view/4492

Изменения со стороны сердечно-сосудистой системы являются наиболее частыми при нарушении функции щитовидной железы. Понимание механизмов действия гормонов щитовидной железы на кардиоваскулярную систему может объяснить изменения сердечного выброса, сердечной сократимости, артериального давления, нарушения ритма, связанные с дисфункцией щитовидной железы. В данном обзоре представлены современные данные об изменениях сердечно-сосудистой системы, возникающих при тиреотоксикозе и гипотиреозе, а также изменения со стороны щитовидной железы на фоне хронической сердечно-сосудистой недостаточности.

The cardiovascular signs and symptoms of thyroid disease are some of the most clinically relevant findings that accompany both hyperthyroidism and hypothyroidism. On the basis of the understanding of the mechanisms of thyroid hormone action on the heart and cardiovascular system, it is possible to explain the changes in cardiac output, cardiac contractility, blood pressure and rhythm disturbances that result from thyroid dysfunction. In the present review will integrate what is known about the mechanisms of thyroid hormone action on the heart and the alterations in thyroid hormone metabolism that accompany chronic congestive heart failure.

щитовидная железатиреотоксикозгипотиреозсердцеthyroid glandhyperthyroidismhypothyroidismheartReferencesCanaris G.J., Manowitz N.R., Mayor G., Ridgway E.C. The Colorado thyroid disease prevalence study // Arch. Intern. Med. 2000. V. 160. P. 526–530.Canaris G.J., Manowitz N.R., Mayor G., Ridgway E.C. The Colorado thyroid disease prevalence study // Arch. Intern. Med. 2000. V. 160. P. 526–530.Biondi B., Palmieri E.A., Lombardi G., Fazio S. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism // J. Clin. Endocrinol. Metab. 2002. V. 87. P. 968–974.Biondi B., Palmieri E.A., Lombardi G., Fazio S. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism // J. Clin. Endocrinol. Metab. 2002. V. 87. P. 968–974.Everts M.E., Verhoeven F.A., Bezstarosti K. et al. Uptake of thyroid hormones in neonatal rat cardiac myocytes // Endocrinol. 1996. V. 137. P. 4235–4242.Everts M.E., Verhoeven F.A., Bezstarosti K. et al. Uptake of thyroid hormones in neonatal rat cardiac myocytes // Endocrinol. 1996. V. 137. P. 4235–4242.Klein I., Danzi S. Thyroid Disease and the Heart // Circulat. 2007. V. 116. P. 1725–1735Klein I., Danzi S. Thyroid Disease and the Heart // Circulat. 2007. V. 116. P. 1725–1735Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system // N. Engl. J. Med. 2001. V. 344. P. 501–509.Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system // N. Engl. J. Med. 2001. V. 344. P. 501–509.Danzi S., Klein I. Thyroid hormone and the cardiovascular system // Minerva Endocrinologica. 2004. V. 29. P. 139–150.Danzi S., Klein I. Thyroid hormone and the cardiovascular system // Minerva Endocrinologica. 2004. V. 29. P. 139–150.Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibrillation // Stroke. 1988. V. 19. P. 15–18.Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibrillation // Stroke. 1988. V. 19. P. 15–18.Krahn A.D., Klein G.J., Kerr C.R. et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators // Arch. Intern. Med. 1996. V. 156. P. 2221–2224.Krahn A.D., Klein G.J., Kerr C.R. et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators // Arch. Intern. Med. 1996. V. 156. P. 2221–2224.Duntas L.H. Thyroid disease and lipids. Thyroid. 2002. V. 12. P. 287–293.Duntas L.H. Thyroid disease and lipids. Thyroid. 2002. V. 12. P. 287–293.Nakazawa H.K., Sakurai K., Hamada N., Momotani N., Ito K. Management of atrial fibrillation in the post-thyrotoxic state // Am. J. Med. 1982. V. 72. P. 903–906.Nakazawa H.K., Sakurai K., Hamada N., Momotani N., Ito K. Management of atrial fibrillation in the post-thyrotoxic state // Am. J. Med. 1982. V. 72. P. 903–906.Gilligan D.M., Ellenbogen K.A., Epstein A.E. The management of atrial fibrillation // Am. J. Med. 1996. V. 101. P. 413–421.Gilligan D.M., Ellenbogen K.A., Epstein A.E. The management of atrial fibrillation // Am. J. Med. 1996. V. 101. P. 413–421.Sawin C.T., Geller A., Wolf P.A. et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons // N. Engl. J. Med. 1994. V. 331. P. 1249–1252Sawin C.T., Geller A., Wolf P.A. et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons // N. Engl. J. Med. 1994. V. 331. P. 1249–1252Biondi B., Fazio S., Carella C. et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving longterm suppressive therapy with levothyroxine // J. Clin. Endocrinol. Metab. 1994. V. 78. P. 1028–1033.Biondi B., Fazio S., Carella C. et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving longterm suppressive therapy with levothyroxine // J. Clin. Endocrinol. Metab. 1994. V. 78. P. 1028–1033.Forfar J.C., Muir A.L., Sawers S.A., Toft A.D. Abnormal left ventricular function in hyperthyroidism: evidence for possible reversible cardiomyopathy // N. Engl. J. Med. 1982. V. 307. P. 1165–1170.Forfar J.C., Muir A.L., Sawers S.A., Toft A.D. Abnormal left ventricular function in hyperthyroidism: evidence for possible reversible cardiomyopathy // N. Engl. J. Med. 1982. V. 307. P. 1165–1170.Шульгина В.Ю., Фадеев В.В., Мельниченко Г.А. Поражение миокарда при тиреотоксикозе: особенности течения, исходы, отдаленный прогноз // Клин. и экспер. тиреоидол. 2006. Т. 2. № 4. С. 21–30.Шульгина В.Ю., Фадеев В.В., Мельниченко Г.А. Поражение миокарда при тиреотоксикозе: особенности течения, исходы, отдаленный прогноз // Клин. и экспер. тиреоидол. 2006. Т. 2. № 4. С. 21–30.Kahaly G., Mohr-Kahaly S., Hellermann // J. Heart. Thyroid. Wien. 1994.Kahaly G., Mohr-Kahaly S., Hellermann // J. Heart. Thyroid. Wien. 1994.Kahaly G. Graves’ disease and mitral valve prolapse // JAMA. 1987. V. 257. P. 22–28.Kahaly G. Graves’ disease and mitral valve prolapse // JAMA. 1987. V. 257. P. 22–28.Klein I., Ojamaa K. The cardiovascular system in hypothyroidism / In: L.E. Braverman, R.D. Utiger // Eds. Werner & Ingbar’s the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2000. P. 777–782.Klein I., Ojamaa K. The cardiovascular system in hypothyroidism / In: L.E. Braverman, R.D. Utiger // Eds. Werner & Ingbar’s the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2000. P. 777–782.Bengel F.M., Nekolla S.G., Ibrahim T. Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging // J. Clin. Endocrinol. Metab. 2000. V. 85. P. 1822–1827.Bengel F.M., Nekolla S.G., Ibrahim T. Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging // J. Clin. Endocrinol. Metab. 2000. V. 85. P. 1822–1827.Ojamaa K., Sabet A., Kenessey A. et al. Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific // Endocrinol. 1999. V. 140. P. 3170–3176.Ojamaa K., Sabet A., Kenessey A. et al. Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific // Endocrinol. 1999. V. 140. P. 3170–3176.Cooper D., Halpern R., Wood L.C. et al. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial // Ann. Intern. Med. 1984. V. 101. P. 18–24.Cooper D., Halpern R., Wood L.C. et al. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial // Ann. Intern. Med. 1984. V. 101. P. 18–24.Hak A.E., Pols H.A.P, Visser T.J. et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study // Ann. Intern. Med. 2000. C. 132. P. 270–278.Hak A.E., Pols H.A.P, Visser T.J. et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study // Ann. Intern. Med. 2000. C. 132. P. 270–278.Franklyn J.A., Gammage M.D., Ramsden D.B., Sheppard M.C. Thyroid status in patients after acute myocardial infarction // Clin. Sci (Colch). 1984. V. 67. P. 585–590.Franklyn J.A., Gammage M.D., Ramsden D.B., Sheppard M.C. Thyroid status in patients after acute myocardial infarction // Clin. Sci (Colch). 1984. V. 67. P. 585–590.Hamilton M.A., Stevenson L.W., Fonarow G.C. et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure // Am. J. Cardiol. 1998. V. 81. P. 443–447.Hamilton M.A., Stevenson L.W., Fonarow G.C. et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure // Am. J. Cardiol. 1998. V. 81. P. 443–447.Moruzzi P., Doria E., Agostoni P.G. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy // Am. J. Med. 1996. V. 101. P. 461–467.Moruzzi P., Doria E., Agostoni P.G. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy // Am. J. Med. 1996. V. 101. P. 461–467.Holland F.W., Brown P.S.Jr., Weintraub B.D., Clark R.E. Cardiopulmonary bypass and thyroid function: a “euthyroid sick syndrome” // Ann. Thorac. Surg. 1991. V. 52. P. 46–50.Holland F.W., Brown P.S.Jr., Weintraub B.D., Clark R.E. Cardiopulmonary bypass and thyroid function: a “euthyroid sick syndrome” // Ann. Thorac. Surg. 1991. V. 52. P. 46–50.Novitzky D., Fontanet H., Snyder M. et al. Impact of triiodothyronine on the survival of high-risk patients undergoing open heart surgery // Cardiology. 1996. V. 87. P. 509–515.Novitzky D., Fontanet H., Snyder M. et al. Impact of triiodothyronine on the survival of high-risk patients undergoing open heart surgery // Cardiology. 1996. V. 87. P. 509–515.Cimochowski G.E., Harostock M.D., Foldes P.J. Minimal operative mortality in patients undergoing coronary artery bypass with significant left ventricular dysfunction by maximization of metabolic and mechanical support // Thorac. Cardiovasc. Surg. 1997. V. 113. P. 655–666.Cimochowski G.E., Harostock M.D., Foldes P.J. Minimal operative mortality in patients undergoing coronary artery bypass with significant left ventricular dysfunction by maximization of metabolic and mechanical support // Thorac. Cardiovasc. Surg. 1997. V. 113. P. 655–666.Klemperer J.D., Klein I.L., Ojamaa K. et al. Triiodothyronine therapy the incidence of atrial fibrillation after cardiac operations // Ann. Thorac. Lowers. Surg. 1996. V. 61. P. 1323–1329.Klemperer J.D., Klein I.L., Ojamaa K. et al. Triiodothyronine therapy the incidence of atrial fibrillation after cardiac operations // Ann. Thorac. Lowers. Surg. 1996. V. 61. P. 1323–1329.Mullis-Janson S.L., Argenziano M., Corwin S. et al. A randomized doubleblind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery // J. Thor. Cardiovasc. Surg. 1999. V. 117. P. 1128–1134.Mullis-Janson S.L., Argenziano M., Corwin S. et al. A randomized doubleblind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery // J. Thor. Cardiovasc. Surg. 1999. V. 117. P. 1128–1134.Bennett-Guerrero E., Jimenez J.L., White W.D. et al. Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery: a randomized, doubleblind, placebo-controlled trial // JAMA. 1996. V. 275. P. 687–692.Bennett-Guerrero E., Jimenez J.L., White W.D. et al. Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery: a randomized, doubleblind, placebo-controlled trial // JAMA. 1996. V. 275. P. 687–692.Bettendorf M., Schmidt K.G., Tiefenbacher U. et al. Transient secondary hypothyroidism in children after cardiac surgery // Pediatr. Res. 1997. V. 41. P. 375–379.Bettendorf M., Schmidt K.G., Tiefenbacher U. et al. Transient secondary hypothyroidism in children after cardiac surgery // Pediatr. Res. 1997. V. 41. P. 375–379.Saatvedt K., Lindberg H. Depressed thyroid function following pediatric cardiopulmonary bypass: association with interleukin-6 release? Scand // J. Thorac. Cardiovasc. Surg. 1996. V. 30. P. 61–64.Saatvedt K., Lindberg H. Depressed thyroid function following pediatric cardiopulmonary bypass: association with interleukin-6 release? Scand // J. Thorac. Cardiovasc. Surg. 1996. V. 30. P. 61–64.Mainwaring R.D., Lamberti J.J., Carter T.L.Jr., Nelson J.C. Reduction in triiodothyronine levels following modified Fontan procedure // J. Card. Surg. 1994. V. 9. P. 322–331.Mainwaring R.D., Lamberti J.J., Carter T.L.Jr., Nelson J.C. Reduction in triiodothyronine levels following modified Fontan procedure // J. Card. Surg. 1994. V. 9. P. 322–331.Chowdhury D., Parnell V., Ojamaa K. et al. Usefulness of triiodothyronine treatment after surgery for complex congenital heart disease in infants and children // Am. J. Cardiol. 1999. V. 84. P. 1107–1109.Chowdhury D., Parnell V., Ojamaa K. et al. Usefulness of triiodothyronine treatment after surgery for complex congenital heart disease in infants and children // Am. J. Cardiol. 1999. V. 84. P. 1107–1109.

The authors declare that there are no conflicts of interest present.